CN114272257A - Application of miR-204 in diagnosis or treatment of atherosclerosis - Google Patents
Application of miR-204 in diagnosis or treatment of atherosclerosis Download PDFInfo
- Publication number
- CN114272257A CN114272257A CN202210033057.6A CN202210033057A CN114272257A CN 114272257 A CN114272257 A CN 114272257A CN 202210033057 A CN202210033057 A CN 202210033057A CN 114272257 A CN114272257 A CN 114272257A
- Authority
- CN
- China
- Prior art keywords
- mir
- expression
- macrophages
- inhibit
- foaming
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108091031479 miR-204 stem-loop Proteins 0.000 title claims abstract description 232
- 108091089766 miR-204-3 stem-loop Proteins 0.000 title claims abstract description 78
- 108091053626 miR-204-5 stem-loop Proteins 0.000 title claims abstract description 76
- 108091032382 miR-204-1 stem-loop Proteins 0.000 title claims abstract description 73
- 108091085803 miR-204-2 stem-loop Proteins 0.000 title claims abstract description 73
- 108091073500 miR-204-4 stem-loop Proteins 0.000 title claims abstract description 73
- 201000001320 Atherosclerosis Diseases 0.000 title claims abstract description 70
- 238000011282 treatment Methods 0.000 title abstract description 10
- 238000003745 diagnosis Methods 0.000 title abstract description 7
- 108010045374 CD36 Antigens Proteins 0.000 claims abstract description 63
- 230000014509 gene expression Effects 0.000 claims abstract description 60
- 210000002540 macrophage Anatomy 0.000 claims abstract description 57
- 238000005187 foaming Methods 0.000 claims abstract description 34
- 108010051779 histone H3 trimethyl Lys4 Proteins 0.000 claims abstract description 16
- 238000013518 transcription Methods 0.000 claims abstract description 14
- 230000035897 transcription Effects 0.000 claims abstract description 14
- 230000008685 targeting Effects 0.000 claims abstract description 11
- 150000002632 lipids Chemical class 0.000 claims description 46
- 230000008021 deposition Effects 0.000 claims description 35
- 230000002401 inhibitory effect Effects 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 6
- 210000003855 cell nucleus Anatomy 0.000 claims description 5
- 229940079593 drug Drugs 0.000 claims description 5
- 239000003153 chemical reaction reagent Substances 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- 102000049320 CD36 Human genes 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 102000053028 CD36 Antigens Human genes 0.000 abstract description 61
- 102100034184 Macrophage scavenger receptor types I and II Human genes 0.000 abstract description 24
- 101710134306 Macrophage scavenger receptor types I and II Proteins 0.000 abstract description 24
- 230000000694 effects Effects 0.000 abstract description 19
- 102000014452 scavenger receptors Human genes 0.000 abstract description 11
- 108010078070 scavenger receptors Proteins 0.000 abstract description 11
- 210000000805 cytoplasm Anatomy 0.000 abstract description 7
- 230000007246 mechanism Effects 0.000 abstract description 5
- 208000024172 Cardiovascular disease Diseases 0.000 abstract description 4
- 210000004027 cell Anatomy 0.000 description 30
- 230000002829 reductive effect Effects 0.000 description 23
- 241000699666 Mus <mouse, genus> Species 0.000 description 22
- 108010071584 oxidized low density lipoprotein Proteins 0.000 description 19
- 238000002474 experimental method Methods 0.000 description 18
- 239000003112 inhibitor Substances 0.000 description 18
- 210000003291 sinus of valsalva Anatomy 0.000 description 18
- 238000000034 method Methods 0.000 description 14
- 238000010186 staining Methods 0.000 description 14
- 108700008625 Reporter Genes Proteins 0.000 description 12
- 108020004999 messenger RNA Proteins 0.000 description 12
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 10
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 10
- 108060001084 Luciferase Proteins 0.000 description 9
- 239000005089 Luciferase Substances 0.000 description 9
- 238000007901 in situ hybridization Methods 0.000 description 9
- 101100256256 Mus musculus Scara3 gene Proteins 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 8
- 108091036066 Three prime untranslated region Proteins 0.000 description 8
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 8
- 210000004940 nucleus Anatomy 0.000 description 8
- 108020004414 DNA Proteins 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- 210000003462 vein Anatomy 0.000 description 7
- NPGIHFRTRXVWOY-UHFFFAOYSA-N Oil red O Chemical compound Cc1ccc(C)c(c1)N=Nc1cc(C)c(cc1C)N=Nc1c(O)ccc2ccccc12 NPGIHFRTRXVWOY-UHFFFAOYSA-N 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 210000001185 bone marrow Anatomy 0.000 description 6
- 210000000497 foam cell Anatomy 0.000 description 6
- 239000013612 plasmid Substances 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 206010028851 Necrosis Diseases 0.000 description 5
- 238000011529 RT qPCR Methods 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 238000000465 moulding Methods 0.000 description 5
- 230000017074 necrotic cell death Effects 0.000 description 5
- 230000001338 necrotic effect Effects 0.000 description 5
- 230000002018 overexpression Effects 0.000 description 5
- 239000002243 precursor Substances 0.000 description 5
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 4
- 102000008186 Collagen Human genes 0.000 description 4
- 108010035532 Collagen Proteins 0.000 description 4
- 108010033040 Histones Proteins 0.000 description 4
- 208000037273 Pathologic Processes Diseases 0.000 description 4
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 4
- 238000003766 bioinformatics method Methods 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 235000012000 cholesterol Nutrition 0.000 description 4
- 229920001436 collagen Polymers 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 235000009200 high fat diet Nutrition 0.000 description 4
- 238000010172 mouse model Methods 0.000 description 4
- 230000009054 pathological process Effects 0.000 description 4
- 210000005259 peripheral blood Anatomy 0.000 description 4
- 239000011886 peripheral blood Substances 0.000 description 4
- 230000001124 posttranscriptional effect Effects 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 238000003762 quantitative reverse transcription PCR Methods 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 230000002195 synergetic effect Effects 0.000 description 4
- 238000001262 western blot Methods 0.000 description 4
- 101150037123 APOE gene Proteins 0.000 description 3
- 101100216294 Danio rerio apoeb gene Proteins 0.000 description 3
- SHIBSTMRCDJXLN-UHFFFAOYSA-N Digoxigenin Natural products C1CC(C2C(C3(C)CCC(O)CC3CC2)CC2O)(O)C2(C)C1C1=CC(=O)OC1 SHIBSTMRCDJXLN-UHFFFAOYSA-N 0.000 description 3
- 101000934372 Homo sapiens Macrosialin Proteins 0.000 description 3
- 102100025136 Macrosialin Human genes 0.000 description 3
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- QONQRTHLHBTMGP-UHFFFAOYSA-N digitoxigenin Natural products CC12CCC(C3(CCC(O)CC3CC3)C)C3C11OC1CC2C1=CC(=O)OC1 QONQRTHLHBTMGP-UHFFFAOYSA-N 0.000 description 3
- SHIBSTMRCDJXLN-KCZCNTNESA-N digoxigenin Chemical compound C1([C@@H]2[C@@]3([C@@](CC2)(O)[C@H]2[C@@H]([C@@]4(C)CC[C@H](O)C[C@H]4CC2)C[C@H]3O)C)=CC(=O)OC1 SHIBSTMRCDJXLN-KCZCNTNESA-N 0.000 description 3
- 210000003038 endothelium Anatomy 0.000 description 3
- 239000002679 microRNA Substances 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 210000004980 monocyte derived macrophage Anatomy 0.000 description 3
- 210000005087 mononuclear cell Anatomy 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000002103 transcriptional effect Effects 0.000 description 3
- 241000701161 unidentified adenovirus Species 0.000 description 3
- 241001164825 Adeno-associated virus - 8 Species 0.000 description 2
- 108010092160 Dactinomycin Proteins 0.000 description 2
- 241000702421 Dependoparvovirus Species 0.000 description 2
- 102000006947 Histones Human genes 0.000 description 2
- 108700011259 MicroRNAs Proteins 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 206010000891 acute myocardial infarction Diseases 0.000 description 2
- 230000000685 anti-plasmid Effects 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 210000004979 bone marrow derived macrophage Anatomy 0.000 description 2
- 210000001715 carotid artery Anatomy 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 208000026106 cerebrovascular disease Diseases 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 229960000640 dactinomycin Drugs 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000010166 immunofluorescence Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 210000003024 peritoneal macrophage Anatomy 0.000 description 2
- 230000007505 plaque formation Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 229940071127 thioglycolate Drugs 0.000 description 2
- CWERGRDVMFNCDR-UHFFFAOYSA-M thioglycolate(1-) Chemical compound [O-]C(=O)CS CWERGRDVMFNCDR-UHFFFAOYSA-M 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 101150044789 Cap gene Proteins 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- 101000777658 Homo sapiens Platelet glycoprotein 4 Proteins 0.000 description 1
- 108090000604 Hydrolases Proteins 0.000 description 1
- 102000004157 Hydrolases Human genes 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 241000581650 Ivesia Species 0.000 description 1
- 101710172072 Kexin Proteins 0.000 description 1
- 102000000853 LDL receptors Human genes 0.000 description 1
- 108010001831 LDL receptors Proteins 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 108010057163 Ribonuclease III Proteins 0.000 description 1
- 102000003661 Ribonuclease III Human genes 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 108700009124 Transcription Initiation Site Proteins 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000004700 cellular uptake Effects 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000027288 circadian rhythm Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 210000003989 endothelium vascular Anatomy 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- OLNTVTPDXPETLC-XPWALMASSA-N ezetimibe Chemical compound N1([C@@H]([C@H](C1=O)CC[C@H](O)C=1C=CC(F)=CC=1)C=1C=CC(O)=CC=1)C1=CC=C(F)C=C1 OLNTVTPDXPETLC-XPWALMASSA-N 0.000 description 1
- 229960000815 ezetimibe Drugs 0.000 description 1
- 229940125753 fibrate Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 102000051522 human CD36 Human genes 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 231100000225 lethality Toxicity 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000003712 lysosome Anatomy 0.000 description 1
- 230000001868 lysosomic effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 108091070501 miRNA Proteins 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 239000000101 novel biomarker Substances 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000013610 patient sample Substances 0.000 description 1
- 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 1
Images
Landscapes
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention relates to the field of cardiovascular diseases, in particular to application of miR-204 in diagnosis or treatment of atherosclerosis. The invention discovers for the first time that miR-204 has the effect of 'one-rock-two-bird', two mature bodies thereof, namely miR-204-5p and miR-204-3p, respectively inhibit the expression of scavenger receptors in cytoplasm and nucleus through different mechanisms, miR-204-5p in cytoplasm inhibits SR-A expression through classical seed sequence targeting, and miR-204-3p inhibits the enrichment of H3K27ac and H3K4me3 on CD36 promoter in nucleus so as to inhibit the transcription of CD 36. miR-204 inhibits macrophage foaming and atherosclerosis through the above ways and under double-pipe conditions.
Description
Technical Field
The invention relates to the field of cardiovascular diseases, in particular to application of miR-204 in diagnosis or treatment of atherosclerosis.
Background
Atherosclerosis (AS) is a common chronic metabolic cardiovascular and cerebrovascular disease and also a pathological basis of a plurality of cardiovascular and cerebrovascular diseases, and acute myocardial infarction and stroke caused by AS have extremely high lethality, and become one of the main diseases threatening human health. Therefore, the prevention and treatment of AS has been one of the hot spots of basic and clinical research.
The etiology and pathogenesis of AS are very complex, and its formation is through a series of complex processes, mainly including foaming of macrophages, deposition of lipids under endothelium, infiltration of inflammatory cells under endothelium, formation of lipid necrosis core, proliferation and migration of vascular smooth muscle cells, etc. AS is formed first in the intima layer of blood vessels, in the early stage of the disease course of AS, under various pathogenic factors such AS hyperlipidemia, hypertension and hyperglycemia, oxidized low density lipoprotein (oxLDL) in blood is accumulated under the vascular endothelium, endothelial cells are stimulated to secrete inflammatory factors, mononuclear cells in blood are further recruited to accumulate and adhere under the endothelium, and under the action of cytokines such AS chemokines, the mononuclear cells are differentiated to form macrophages. Macrophages engulf lipid mainly containing oxLDL particles through scavenger receptors such as SR-A, CD36 on cell membranes, and lipid droplets are formed in cells and stored, so that the macrophages are further converted into foam cells. Excessive uptake of oxLDL AS the main lipid by foam cells causes apoptosis and necrosis, and the lipid is released and accumulated in an endothelial layer to form early characteristic lipid stripes of AS. AS the course of AS progresses, endothelial cells and smooth muscle cells take up oxLDL-based lipids, excessive lipids accumulate in the cells leading to apoptosis and necrosis, and lipids and necrotic cell debris accumulate on the vessel wall, gradually forming the lipid core of atheromatous plaque. Atheromatous plaque causes narrowing of the vessel lumen, obstructing blood flow, and hardening of the vessel wall. And the foam cells secrete a large amount of hydrolase, so that the plaque stability is reduced, the plaque is easy to fall off from the blood vessel wall, and thrombus is formed, and further cardiovascular diseases such as cerebral apoplexy and acute myocardial infarction are caused.
Therefore, the core of AS occurrence is atheromatous plaque formation, and macrophage uptake of excessive oxLDL and conversion of excessive oxLDL into foam cells are important processes of atheromatous plaque formation, and macrophage foaming plays a key role in AS process. Uptake of oxLDL by macrophages is mainly dependent on the expression level of scavenger receptors on their cell membranes, such as CD36 and SR-A. The main methods for clinically surgically treating AS include drug eluting stents and drug coated balloons. The existing scheme for treating AS mainly reduces the blood lipid level, and statins, ezetimibe, proprotein convertase subtilisin Kexin type 9 inhibitor and fibrates are used for reducing the level of oxidized low-density lipoprotein cholesterol. However, no specific drug is available at present, which can reduce the uptake of oxidized low density lipoprotein cholesterol by cells. If a new treatment strategy can be provided from the perspective of reducing the cellular uptake of oxidized low density lipoprotein, the method has important significance for the prevention and treatment of AS.
Disclosure of Invention
The invention aims to overcome the defects of the prior art and provides an application of miR-204 in diagnosis or treatment of atherosclerosis.
The invention discovers that the expression of microRNA 204 (miR-204 for short) in peripheral blood mononuclear cells of AS patients is reduced compared with that of a normal control group clinically, and miR-204 can effectively reduce the expression of scavenger receptors on macrophage membranes, so that the uptake of oxLDL by macrophages is reduced, and the lipid deposition and foaming of the macrophages are inhibited. Pre-miR-204 is a precursor of miR-204, which is an existing form of miR-204. The Pre-miR-204 is cut into two mature bodies with the length of about 20-24 nt by Dicer enzyme digestion, namely miR-204-5p and miR-204-3 p. miR-204 has the effect of 'Odongshiki'. In one aspect, miR-204-5p inhibits SR-A expression in cytosolic targeting SR-A3' -UTR viA the classical pathway. On the other hand, miR-204-3p affects CD36 histone modification in nucleus so as to inhibit transcriptional activation of the histone modification, thereby reducing expression of CD 36. miR-204 is used AS a novel drug action target, and the detection of peripheral blood miR-204 can be used AS a novel biomarker for diagnosis and prevention of AS diseases.
In order to achieve the purpose, the invention adopts the technical scheme that: provides an application of miR-204 in preparing a medicament for inhibiting lipid deposition and foaming of macrophages.
As a preferred embodiment of the use according to the invention, said inhibition of lipid deposition and foaming of macrophages comprises the prevention or treatment of atherosclerosis.
As a preferred embodiment of the application of the invention, the miR-204 comprises miR-204-5p and miR-204-3 p.
The invention aims to overcome the defects of the prior art and determine or discover the microRNA subtype type playing a key role in AS diseases. According to the invention, a large number of experiments show that the expression of pre-miR-204 is reduced in AS diseases. According to the invention, the miR-204 precursor pre-miR-204 and miR-204 mature body (TuD-miR-204-5p or TuD-miR-204-3p) function are overexpressed on animals by using an adenovirus method, and the result shows that miR-204 overexpression can obviously inhibit the generation and development of AS, and can close the function of miR-204-5p or miR-204-3p, so that the pathological process can be strengthened or promoted. In addition, the invention also finds that the expression level of pre-miR-204 in Peripheral Blood Mononuclear Cells (PBMCs) of AS patients is reduced clinically.
The invention firstly discovers that the expression of the miR-204 precursor is reduced in the AS process. The expression of pre-miR-204 in PBMCs of a blood sample of a clinical patient is detected by RT-qPCR, and the expression of pre-miR-204 in an AS patient is obviously reduced. In Situ Hybridization (ISH) experiments demonstrated a reduction In pre-miR-204 expression In carotid plaques In AS patients. In animal experiments, with normally fed Apoe-/-HFD-fed Apoe compared to mouse-/-The level of pre-miR-204 expression in aortic sinus plaques in mice was also reduced.
The invention discovers that in an AS mouse model, aortic sinus lipid deposition of a mouse injected with AAV-pre-miR-204 via tail vein is obviously reduced, aortic sinus plaque area is reduced, necrotic area in plaque is reduced, plaque stability is improved, and overexpression of pre-miR-204 can inhibit generation and development of AS. And the function of miR-204-5p or miR-204-3p is sealed, so that the pathological process can be strengthened or promoted.
As A preferred embodiment of the application of the invention, the miR-204-5p is targeted to inhibit SR-A expression so as to inhibit lipid deposition and foaming of macrophages.
As A preferred embodiment of the application of the invention, the miR-204-5p inhibits SR-A through the targeting of A classical seed sequence.
As a preferred embodiment of the application of the invention, the miR-204-3p inhibits the transcription of CD36 so as to inhibit the lipid deposition and foaming of macrophages.
As a preferred embodiment of the application of the invention, the miR-204-3p inhibits the enrichment of H3K27ac and H3K4me3 on a CD36 promoter in a cell nucleus so as to inhibit the transcription of CD 36.
In order to clarify the relevant role of miR-204 in lipid deposition and foam cell formation, by separating Bone Marrow Differentiated Macrophages (BMDMs) of mice, carrying out oil red O staining on the cells and carrying out Uptake and Binding detection on the cells, the transfected miR-204-5p mimics or miR-204-3p mimics are found to obviously inhibit macrophage lipid deposition and foaming. In addition, compared with NC-inhibitor, the transfection of miR-204-5p inhibitor or miR-204-3p inhibitor is found to obviously promote lipid deposition and foaming. The results prove that miR-204-5p and miR-204-3p can inhibit macrophage lipid deposition and foaming. In vitro experiments show that miR-204-5p and miR-204-3p can respectively inhibit the expression of scavenger receptors SR-A and CD 36. Through bioinformatics analysis, an evolutionarily conserved miR-204-5p seed sequence is found in A3 '-untranslated region (3' -UTR) region of SR-A. A luciferase reporter gene experiment is carried out in HEK293T cells, and the results show that miR-204-5p mimics are transfected to reduce the activity of an SR-A3' -UTR reporter gene, but when the miR-204-5p seed region on the SR-A reporter gene is mutated, the effect is not influenced. The above results demonstrate that miR-204-5p (3' -UCCGUAUCCUACUGUUUCCCUU-5 ') inhibits its expression by targeting SR-A3' -UTR. And experiments prove that miR-204-3p does not inhibit the expression of CD36 from a post-transcriptional level, and miR-204-3p is combined with a complementary target site in a CD36 promoter through a specific sequence (3 '-UGCAGGGAAACGGAAGGGUCG-5') in a cell nucleus, so that the enrichment of histones H3K27ac and H3K4me3 on the CD36 promoter is reduced, and the CD36 transcription is inhibited.
The invention also provides application of the reagent for detecting miR-204 in preparation of a kit for diagnosing atherosclerosis.
As a preferred embodiment of the application of the invention, the miR-204 comprises Pre-miR-204, miR-204-5p and miR-204-3 p.
As a preferable embodiment of the application of the invention, the reagent for detecting miR-204 comprises a reagent for detecting the expression level of miR-204.
The invention has the beneficial effects that:
miR-204 has the effect of 'one-rock-two-bird', two mature bodies thereof, namely miR-204-5p and miR-204-3p inhibit the expression of scavenger receptors in cytoplasm and nucleus through different mechanisms respectively, miR-204-5p in cytoplasm inhibits SR-A expression through classical seed sequence targeting, and miR-204-3p inhibits the enrichment of H3K27ac and H3K4me3 on CD36 promoter in nucleus so as to inhibit the transcription of CD 36. miR-204 inhibits macrophage foaming and AS through the above approaches in a double-pipe manner.
Drawings
FIG. 1: the expression of miR-204 is reduced in the AS process; wherein, A: collecting peripheral blood of 97 clinical patient samples, wherein the sample grouping condition is 22 normal groups and 75 AS groups, separating PBMCs from the collected peripheral blood, detecting the expression of pre-miR-204 in the PBMCs by using an RT-qPCR technology, and displaying that the expression of the pre-miR-204 in the AS group is lower compared with that of a normal control group; b: ISH staining of pre-miR-204 in carotid arteries of normal and AS-afflicted patients, and Apoe for normal and high-fat feeding-/-ISH staining of pre-miR-204 in mice revealed reduced pre-miR-204 expression in AS lesions compared to controls.
FIG. 2: the overexpression of pre-miR-204 can inhibit the generation and development of AS; wherein, A: AAV-PCSK9 injected into tail vein of 8-week-old mouseDYStarting high-fat feeding to establish an AS mouse model, injecting AAV-LacZ or AAV-pre-miR-204 into tail vein at 12 weeks, continuing high-fat feeding for 20 weeks, taking a mouse heart aortic sinus slice, and staining ISH of the pre-miR-204, wherein the result shows that the pre-miR-204 is successfully overexpressed; b: the aortic sinus section of the mouse heart after molding in fig. 2A was stained with oil red O to detect lipid deposition. The results show a reduction in lipid deposition in the AAV-pre-miR-204 group compared to the control AAV-LacZ; c: the section obtained after molding in fig. 2A was subjected to hematoxylin-eosin (HE) staining, and the size of the aortic sinus plaque area was examined. The results showed a reduction in aortic sinus plaque area in the AAV-pre-miR-204 group compared to the control AAV-LacZ; d: the section obtained after molding in fig. 2A was subjected to hematoxylin-eosin (HE) staining, and the size of necrotic area in aortic sinus plaque was measured. The results show that the necrosis area of aortic sinus plaque in the AAV-pre-miR-204 group is reduced compared with that of the control AAV-LacZ; e: for the above-mentioned FIG. 2And D, performing masson staining on the section subjected to modeling in the step A, and detecting the collagen content of the aortic sinus plaque. The results show that compared with the control AAV-LacZ, the AAV-pre-miR-204 group has more collagen content and stronger plaque stability.
FIG. 3: macrophage closes expression of miR-204-3p or miR-204-5p, and generation and development of AS can be promoted; wherein, A: for 8-week-old Apoe-/-The mouse is fed with high fat to establish an AS mouse model, AAV-TuD-LacZ, AAV-TuD-miR-204-5p or AAV-TuD-204-3p is injected into tail vein at 12 weeks, high fat feeding is continued for 20 weeks, abdominal cavity macrophages are separated, RNA is extracted to carry out RT-qPCR detection on the expression of miR-204-5p and miR-204-3p, and the result shows that the expression of miR-204-5p and miR-204-3p is obviously reduced. B: the mice modeled in fig. 3A were sectioned for cardiac aortic sinus and stained with oil red O to detect lipid deposition. The results showed that lipid deposition was increased in AAV-TuD-204-5p and AAV-TuD-204-3p groups compared with control group AAV-TuD-LacZ. C: the section molded in fig. 3A was subjected to hematoxylin-eosin (HE) staining, and the size of the aortic sinus plaque area was measured. The results showed that the aortic sinus plaque area was increased in the AAV-TuD-204-5p and AAV-TuD-204-3p groups compared to the control group AAV-TuD-LacZ. D: the section obtained after molding in fig. 3A was subjected to hematoxylin-eosin (HE) staining, and the size of necrotic area in aortic sinus plaque was measured. The results showed that the necrosis area of aortic sinus plaque was increased in the AAV-TuD-204-5p and AAV-TuD-204-3p groups compared to the control group AAV-TuD-LacZ. E: the section obtained after molding in FIG. 3A was subjected to Masson staining to detect the collagen content in the aortic sinus plaque. The results show that compared with the control group AAV-TuD-LacZ, the AAV-pre-miR-204 group has less collagen content and weakened plaque stability.
FIG. 4: the high-expression miR-204-3p or miR-204-5p can inhibit the lipid deposition and macrophage foaming of macrophages, and the inhibition of the expression of miR-204-3p or miR-204-5p can promote the lipid deposition and macrophage foaming of macrophages; wherein, A: the method comprises the steps of separating mouse bone marrow-derived macrophages (BMDMs), transfecting miR-204-5p mimics and miR-204-3p mimics, stimulating cells for 24 hours by using oxLDL after 24 hours, carrying out oil red O staining to detect the foaming degree of the cells, and displaying that the transfected miR-204-5 pmmimics or miR-204-3p mimics can obviously inhibit lipid deposition and foaming of the macrophages. The miR-204-5p mimics and the miR-204-3p mimics further inhibit the lipid deposition and foaming of macrophages under the synergistic action. B: macrophage (BMDMs) derived from mouse bone marrow are separated, miR-204-5p mimics and miR-204-3p mimics are transfected, cells are stimulated for 2 hours and 4 hours by using Dil marked oxLDL after 24 hours, and the binding and uptake capacity of the cells to the oxLDL is observed under a laser confocal microscope. The result shows that the miR-204-5p mimics or miR-204-3p mimics transfected by the gene can obviously inhibit the lipid deposition and foaming of macrophages. The miR-204-5p mimics and the miR-204-3p mimics further inhibit the lipid deposition and foaming of macrophages under the synergistic action. C: and (3) separating macrophages (BMDMs) derived from mouse bone marrow, transfecting miR-204-5p inhibitor and miR-204-3p inhibitor, adding oxLDL to stimulate cells for 24 hours after 24 hours, and carrying out oil red O staining to detect the foaming degree of the cells, wherein the result shows that the transfected miR-204-5p inhibitor or miR-204-3p inhibitor can obviously promote the lipid deposition and foaming of the macrophages. The miR-204-5p inhibitor and the miR-204-3p inhibitor further promote the lipid deposition and foaming of macrophages under the synergistic action. D: macrophage (BMDMs) derived from mouse bone marrow are separated, miR-204-5p inhibitor and miR-204-3p inhibitor are transfected, cells are stimulated for 2 hours and 4 hours by using Dil marked oxLDL after 24 hours, and the binding and uptake capacity of the cells to the oxLDL is observed under a laser confocal microscope. The result shows that the miR-204-5p inhibitor or miR-204-3p inhibitor can obviously promote the lipid deposition and foaming of macrophages. The miR-204-5p inhibitor and the miR-204-3 pininhibitor further promote the lipid deposition and foaming of macrophages under the synergistic action.
FIG. 5: miR-204-5p in cytoplasm inhibits SR-A expression through classical seed sequence targeting so AS to inhibit macrophage foaming and AS; wherein, A: NC-mics and miR-204-5 p-mics are transfected by bone marrow derived mouse mononuclear macrophages (BMDMs), thioglycolate differentiated mouse peritoneal macrophages (TEPMs), human monocyte derived macrophages (HDMDs) and mouse monocyte macrophage leukemiA cells (RAW264.7), and expression of scavenger receptors SR-A and CD36 is detected by Western Blot, and the result shows that compared with the NC-mics, the miR-204-5 p-mimics can obviously inhibit the expression of SR-A and do not influence the expression of CD 36. B: a specific mechanism that miR-204-5p inhibits the expression of SR-A is explored, and A section of evolutionarily conserved miR-204-5p seed sequence is found in A3 '-untranslated region (3' -UTR) region of SR-A through bioinformatics analysis. C: a luciferase reporter gene experiment is carried out in HEK293T tool cells, and the results show that miR-204-5p mimics are transfected to reduce the activity of an SR-A3' -UTR reporter gene, and when the miR-204-5p on the SR-A reporter gene is combined with A seed region to be mutated, no influence is caused. The above results demonstrate that miR-204-5p inhibits SR-A expression by targeting SR-A3' -UTR.
FIG. 6: miR-204-3p does not inhibit expression of CD36 by post-transcriptional levels; wherein, A: NC-mics and miR-204-3 p-mics are transfected by bone marrow derived mouse mononuclear macrophages (BMDMs), thioglycolate differentiated mouse peritoneal macrophages (TEPMs), human monocyte derived macrophages (HDMDs) and mouse monocyte macrophage leukemiA cells (RAW264.7), and expression of scavenger receptors SR-A and CD36 is detected by Western Blot, and the result shows that compared with the NC-mics, the miR-204-3 pmmics transfected can obviously inhibit expression of CD36 and does not influence expression of SR-A. B: a specific mechanism of miR-204-3p for inhibiting the expression of CD36 is explored, and a section of miR-204-3p seed sequence which is relatively conserved in evolution is found in a3 '-untranslated region (3' -UTR) region of CD36 through bioinformatics analysis. C: luciferase reporter experiments were performed in HEK293T tool cells and it was found that miR-204-3pmimics transfected had no effect on the activity of the CD36 reporter 3' -UTR, but when the miR-204-3p binding seed region on the CD36 reporter was mutated, the activity was also unaffected. D: NC-m, miR-204-3p mimics and mutants thereof (mutation of a seed sequence for combining miR-204-3p mimics and CD 36) are transfected in HDMDs, and the change of the level of CD36 mRNA is detected. E: NC-m, miR-204-3p mimics and mutants thereof (mutation of a seed sequence for combining miR-204-3p mimics and CD 36) are transfected in HDMDs, and the change of the level of the CD36 protein is detected. F: miR-204-3p mimics were transfected in HMDMs and mRNA expression of CD36 was detected 4 hours later using actinomycin D (5. mu.g/mL) (transcription repression) treatment. As a result, no difference is found in the level change of CD36 mRNA of the transfected NC-mimics and miR-204-3p mimics. The above results demonstrate that miR-204-3p does not inhibit CD36 expression via the classical seed sequence pathway, and does not regulate expression of CD36 at the post-transcriptional level.
FIG. 7: miR-204-3p inhibits the enrichment of H3K27ac and H3K4me3 on a CD36 promoter at the cell nucleus so AS to inhibit the transcription of CD36 and further inhibit macrophage foaming and AS; wherein, A: miR-204-3p in situ hybridization and CD68 immunofluorescence co-staining are carried out on the separated BMDMs and HMDMs, and the result shows that miR-204-3p is distributed in the cell nucleus and the cytoplasm of macrophages. B: miR-204-3p mimics are transfected in HMDMs, the transcriptional activity of newly synthesized CD36 is measured after 24 hours and 48 hours, and the result shows that miR-204-3p can obviously reduce the transcriptional activity of CD 36. C: potential binding sites of miR-204-3p on a human CD36 promoter and a sequence diagram of a mutant CD36 promoter (miR-204-3p and CD36 promoter binding site mutation). D: miR-204-3p mimics are transfected in HEK293T cells, and luciferase activity of a CD36 promoter or a mutant CD36 promoter is detected 48 hours later. The result shows that miR-204-3p inhibits the activity of a CD36 promoter by binding with a CD36 promoter site. E: miR-204-3p mimics are transfected in HMDMs, a ChIP experiment is carried out after 24 hours by using H3K27ac (enhancer and promoter marker) and H3K4me3 (promoter specificity marker) antibodies, purified and enriched DNA fragments are subjected to sequencing analysis, and the result of UCSC genome-brown traps shows that miR-204-3p can obviously reduce the enrichment of H3K27ac and H3K4me3 on a CD36 promoter. F: miR-204-3 pmmics is transfected in HMDMs, a ChIP experiment is carried out 24 hours later by using H3K27ac and H3K4me3 antibodies, and a PCR experiment is carried out on purified and enriched DNA fragments, so that the miR-204-3p can reduce the enrichment of H3K27ac and H3K4me3 on a CD36 proximal promoter. The above results indicate that miR-204-3p inhibits the transcription of CD36 by inhibiting the enrichment of H3K27ac and H3K4me3 histones on the CD36 promoter in the macrophage nucleus.
Detailed Description
To more clearly illustrate the technical solutions of the present invention, the following embodiments are further described, but the present invention is not limited thereto, and these embodiments are only some examples of the present invention.
The biological material source of the invention is as follows:
(1) human carotid artery AS plaque specimens were provided by the first hospital affiliated with zhongshan university.
(2) Normal control and AS patient blood specimens were provided by the second hospital affiliated with the Guangzhou medical university.
(3) HEK293T and RAW264.7 cells were introduced from ATCC in the united states.
(4) The C57BL/6 mice were supplied by the laboratory animal center of Zhongshan university, Apoe-/-The mice were provided by the laboratory animal technology, Inc. of Weitonglihua, Beijing.
(5)pAAV/D374Y-hPCSK9(PCSK9DY) The plasmid was supplied by doctor Bentzon.
Example 1 decreased expression of miR-204 in AS Process
(1) Collecting peripheral blood of a clinical patient, separating Peripheral Blood Mononuclear Cells (PBMC) by using a whole blood mononuclear cell separation kit, collecting PBMC to extract RNA, performing reverse transcription to obtain cDNA, and performing fluorescence real-time quantitative PCR to detect the expression of pre-miR-204 in the PBMC. As a result, AS shown in FIG. 1A, the expression of pre-miR-204 was significantly reduced in AS patients.
(2) ISH experiments used a double Digoxigenin (DIG) -labeled Locked Nucleic Acid (LNA) probe to recognize the pre-miR-204 end loop for detection of miR-204 precursor, the sequence of DIG-labeled pre-miR-204 was 5'-GTCCACGAGTCACATGAAGAAAGACTGTAG-3' (SEQ ID NO: 1), paraffin-deparaffinized and rehydrated sections of paraffin tissue were treated with proteinase K to inactivate endogenous nucleases, and the probes were then diluted in hybridization buffer and incubated at 54 ℃ for 1 hour. After in situ hybridization, observation is carried out under a microscope. The results are shown in FIG. 1B, with a decrease in pre-miR-204 expression in AS patients and mouse carotid plaques.
Example 2 miR-204 inhibits AS formation
(1) AAV-pre-miR-204, AAV-TuD-miR-204-5p and AAV-TuD-miR-204-3p are prepared.
The entire sequence of the miR-204 precursor (pre-miR-204, SEQ ID NO: 1) as well as the miR-204-5p decoy (TuD) (5'-AGGCATAGGATGACAAAGGGAA-3', SEQ ID NO: 2) and miR-204-3p decoy (TuD) (5'-ACGTCCCTTTGCCTTC CCAGC-3', SEQ ID NO: 3) sequences were synthesized and cloned into the pAAV-MCS vector, and the CD68 promoter was inserted upstream of the coding sequence to ensure that the plasmid was macrophage-specific expressed. The plasmids are respectively co-transfected into HEK293T cells together with pAAV2/8 antiplasmid and pAAV helper plasmid carrying AAV rep/cap genes by PEI liposome transfection method to generate AAV8 adenoviruses (AAV-pre-miR-204, AAV-TuD-miR-204-5p and AAV-TuD-miR-204-3p), and AAV-LacZ is used as negative control. Viral titers were measured by PCR with vector-specific primers.
(2) Preparation of AS mouse model
AAV-PCSK9DYAnd (5) establishing an induced mouse AS model. AAV-PCSK9DYCan target and recognize the LDL receptor of the liver, degrade the LDL-R in lysosome and have the similar action to the LDL-R-/-Mice induced AS. To construct AAV-PCSK9DYpAAV/D374Y-hPCSK9(PCSK 9) driven by ApoEHCR-hAAT promoterDY) The plasmids respectively carry AAV rep&The pAAV2/8 antiplasmid and pAAV helper plasmid of cap gene were co-transfected into HEK293T cells to generate AAV8 adenovirus (AAV-PCSK 9)DY) AAV-LacZ was used as a negative control. Viral titers were measured by PCR using vector-specific primers. We injected AAV-PCSK9 into tail vein of 8 week old male miceDY(1×1011vg/mouse), mice were given High Fat Diet (HFD) (40% fat, 11.4% sucrose, 1.25% cholesterol), and were fed for 12 weeks to induce an AS disease model.
Apoe-/-And (5) establishing an induced mouse AS model. The invention selects the Apoe with SPF grade of 8 weeks old-/-Male mice were given High Fat Diet (HFD) (40% fat, 11.4% sucrose, 1.25% cholesterol) and fed for 12 weeks to induce an AS disease model. The environmental temperature of all experimental mice is 20-25 ℃, the relative humidity is 50-60%, and the 12-hour illumination period simulates circadian rhythm. All animals were housed in the SPF animal laboratory, the animal laboratory center of university of zhongshan, and the experiment was approved by the animal ethics committee of university of zhongshan.
(3) Results of the experiment
The results are shown in FIG. 2, by comparing AAV-PCSK9DYAAV-pre-miR-204 is injected into the tail vein of the induced AS mouse, the lipid deposition of the mouse is obviously reduced, the aortic sinus plaque area is reduced, the necrotic area in the plaque is reduced, the aortic sinus plaque stability is improved, and the over-expression of pr is shownThe e-miR-204 can inhibit the generation and development of AS.
As shown in fig. 3, by applying Apoe-/-The pathological process can be strengthened or promoted by injecting AAV-TuD-miR-204-5p and AAV-TuD-miR-204-3p into mouse tail vein to seal the expression of macrophage miR-204-5p or miR-204-3 p. RT-qPCR results show that the expression of miR-204-5p or miR-204-3p is remarkably inhibited. And the blocking of the expression of macrophage miR-204-5p or miR-204-3p can strengthen or promote the pathological process.
Example 3 miR-204 can inhibit macrophage lipid deposition and foaming
To elucidate the relevant role of miR-204 in lipid deposition and foam cell formation, cells were stained for oil red O and tested for upstake and Binding by isolating mouse BMDMs (mouse bone marrow-derived macrophages) and Dil-labeled oxLDL.
The result is shown in FIG. 4, and the miR-204-5p mimics or miR-204-3p mimics transfected by the method can obviously inhibit lipid deposition and foaming. Compared with NC-inhibitor, miR-204-5p inhibitor or miR-204-3p inhibitor transfected by the method can obviously promote lipid deposition and foaming. The results prove that the overexpression of miR-204-5p and miR-204-3p can inhibit macrophage lipid deposition and foaming.
Wherein, the miR-204-3p mimics and the miR-204-5p mimics are synthesized and provided by Suzhou Jima company, and the sequences are as follows:
example 4 miR-204-5p inhibits its expression by targeting the scavenger receptor SR-A3' -UTR
miR-204-5p mimics are transfected in various macrophages in vitro, and cell proteins are extracted for carrying out Western blotting to find that miR-204-5p can obviously reduce the expression of scavenger receptor SR-A, and has no influence on scavenger receptor CD 36. In view of the fact that miRNA can inhibit the expression of A target gene by targeting A3' -untranslated region (3' -UTR) of target gene mRNA, A section of miR-204-5p seed sequence which is evolutionarily conserved is found in the 3' -UTR region of SR-A through bioinformatics analysis.
Luciferase reporter experiments were performed in HEK293T tool cells: inserting A3' -UTR sequence of SR-A mRNA into A reporter gene vector, co-transferring into miR-204-5p mimics, and detecting luciferase activity after 48 hours. As shown in FIG. 5C, the activity of the SR-A3' -UTR reporter gene is reduced by transfecting miR-204-5p mimics, and when the miR-204-5p seed region on the SR-A reporter gene is mutated, the influence is avoided. The above results demonstrate that miR-204-5p (3' -UCCGUAUCCUACUGUUUCCCUU-5 ', SEQ ID NO: 10) inhibits its expression by targeting SR-A3' -UTR.
Example 5 miR-204-3p inhibits the transcription of the scavenger receptor CD36 in the nucleus
miR-204-3p mimics are transfected in various macrophages in vitro, and cell proteins are extracted for carrying out Western blotting to find that miR-204-3p can obviously reduce the expression of scavenger receptor CD36 without influencing scavenger receptor SR-A.
Next, the mechanism of inhibiting CD36 expression by miR-204-3p is explored, and a section of miR-204-3p seed sequence which is relatively conserved in evolution is found in the 3' -UTR region of CD 36. Therefore, luciferase reporter experiments were developed in HEK293T tool cells: inserting a3' -UTR sequence of CD36 mRNA into a reporter gene vector, co-transferring miR-204-3p mimics, and detecting luciferase activity after 48 hours. As shown in FIG. 6C, the miR-204-3p mimics transfected has no effect on the activity of the CD 363' -UTR reporter gene, but has no effect when the miR-204-3p seed region on the CD36 reporter gene is mutated. In addition, human monocyte-derived macrophages (HMDMs) are isolated, miR-204-3p mimics and miR-204-3 pmmics-mut (a mutant of a predicted binding sequence of miR-204-3p and CD36 mRNA 3' -UTR) are transfected, and then the CD36 protein and mRNA levels are detected, so that the result shows that miR-204-3p can remarkably reduce the CD36 protein and mRNA levels, and the CD36 protein and mRNA levels are still reduced after the binding sequence is mutated. This indicates that miR-204-3p does not inhibit the expression of CD36 by this seed sequence.
Isolated HMDMs were transfected with miR-204-3p mimics and incubated with actinomycin D (ActD, 5. mu.g/mL) 4 hours later to inhibit mRNA synthesis and interfere with the transcription process of the cells. The results are shown in FIG. 6, and miR-204-3p does not change the half-life of CD36 mRNA. This indicates that miR-204-3p does not inhibit the expression of CD36 from the post-transcriptional level.
The results of our study found that miR-204-3p affects the transcription of CD36 in the nucleus. First, miR-204-3p in-situ hybridization and CD68 immunofluorescence co-staining are carried out on separated BMDMs and HMDMs, and the result shows that miR-204-3p is distributed in the nucleus and the cytoplasm of macrophages. miR-204-3p can obviously reduce the transcriptional activity of CD 36. Through RNAhybrid sequence prediction analysis, a conserved miR-204-3p potential binding site is located 100bp upstream of the transcription initiation site of the CD36 promoter. miR-204-3p mimics are subsequently transfected in HEK293T cells, and the luciferase activity of the CD36 promoter or the mutant CD36 promoter is detected 48 hours later. The results are shown in FIG. 7, and miR-204-3p inhibits the activity of CD36 promoter by binding to CD36 promoter site. miR-204-3p mimics are transfected in HMDMs, an H3K27ac and H3K4me3 antibody are used for performing a ChIP experiment after 24 hours, purified and enriched DNA fragments are subjected to sequencing analysis, and the result of UCSC genome-brown trap shows that miR-204-3p can obviously reduce the peak value of H3K27ac and H3K4me3 on a CD36 promoter. miR-204-3p mimics are transfected in HMDMs, a ChIP experiment is carried out by using H3K27ac and H3K4me3 antibodies after 24 hours, PCR experiments are carried out on purified and enriched DNA fragments, and the fact that miR-204-3p can reduce the enrichment of H3K27ac and H3K4me3 on a CD36 proximal promoter is clear. The above results show that miR-204-3p binds to a complementary target site in the CD36 promoter through a specific sequence (3 '-aUGCAGGGAAACGGAAGGGUCG-5', SEQ ID NO: 11) in the macrophage nucleus, so that the enrichment of histones H3K27ac and H3K4me3 on the CD36 promoter is reduced, and the transcription of CD36 is inhibited.
Finally, it should be noted that the above embodiments are only used for illustrating the technical solutions of the present invention and not for limiting the protection scope of the present invention, and although the present invention is described in detail with reference to the preferred embodiments, it should be understood by those skilled in the art that modifications or equivalent substitutions can be made on the technical solutions of the present invention without departing from the spirit and scope of the technical solutions of the present invention.
SEQUENCE LISTING
<110> Zhongshan university
<120> application of miR-204 in diagnosis or treatment of atherosclerosis
<130> 2022.01.05
<160> 11
<170> PatentIn version 3.3
<210> 1
<211> 30
<212> DNA
<213> Artificial sequence
<400> 1
gtccacgagt cacatgaaga aagactgtag 30
<210> 2
<211> 22
<212> DNA
<213> Artificial sequence
<400> 2
aggcatagga tgacaaaggg aa 22
<210> 3
<211> 21
<212> DNA
<213> Artificial sequence
<400> 3
acgtcccttt gccttcccag c 21
<210> 4
<211> 22
<212> RNA
<213> Artificial sequence
<400> 4
uucccuuugu cauccuaugc cu 22
<210> 5
<211> 22
<212> RNA
<213> Artificial sequence
<400> 5
gcauaggaug acaaagggaa uu 22
<210> 6
<211> 21
<212> RNA
<213> Artificial sequence
<400> 6
gcugggaagg caaagggacg u 21
<210> 7
<211> 21
<212> RNA
<213> Artificial sequence
<400> 7
gucccuuugc cuucccagcu u 21
<210> 8
<211> 22
<212> RNA
<213> Artificial sequence
<400> 8
aggcauagga ugacaaaggg aa 22
<210> 9
<211> 21
<212> RNA
<213> Artificial sequence
<400> 9
acgucccuuu gccuucccag c 21
<210> 10
<211> 22
<212> RNA
<213> Artificial sequence
<400> 10
uccguauccu acuguuuccc uu 22
<210> 11
<211> 22
<212> RNA
<213> Artificial sequence
<400> 11
augcagggaa acggaagggu cg 22
Claims (10)
- Application of miR-204 in preparation of medicines for inhibiting lipid deposition and foaming of macrophages.
- 2. The use of claim 1, wherein said inhibiting lipid deposition and foaming of macrophages comprises preventing or treating atherosclerosis.
- 3. The use of claim 1, wherein said miR-204 comprises miR-204-5p and miR-204-3 p.
- 4. The use of claim 3, wherein the miR-204-5p is targeted to inhibit SR- A expression and thus inhibit lipid deposition and foaming of macrophages.
- 5. The use of claim 4, wherein miR-204-5p inhibits SR-A by classical seed sequence targeting.
- 6. The use of claim 3, wherein the miR-204-3p inhibits transcription of CD36, thereby inhibiting lipid deposition and foaming of macrophages.
- 7. The use of claim 1, wherein the miR-204-3p inhibits the enrichment of H3K27ac and H3K4me3 on the CD36 promoter at the cell nucleus to inhibit transcription of CD 36.
- 8. Application of a reagent for detecting miR-204 in preparation of a kit for diagnosing atherosclerosis.
- 9. The use of claim 8, wherein said miR-204 comprises Pre-miR-204, miR-204-5p, and miR-204-3 p.
- 10. The use of claim 8, wherein the agent for detecting miR-204 comprises an agent for detecting the expression level of miR-204.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210033057.6A CN114272257B (en) | 2022-01-12 | 2022-01-12 | Application of miR-204-5p mimics or miR-204-3p mimics in preparation of drugs for treating atherosclerosis |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210033057.6A CN114272257B (en) | 2022-01-12 | 2022-01-12 | Application of miR-204-5p mimics or miR-204-3p mimics in preparation of drugs for treating atherosclerosis |
Publications (2)
Publication Number | Publication Date |
---|---|
CN114272257A true CN114272257A (en) | 2022-04-05 |
CN114272257B CN114272257B (en) | 2022-11-04 |
Family
ID=80880981
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210033057.6A Active CN114272257B (en) | 2022-01-12 | 2022-01-12 | Application of miR-204-5p mimics or miR-204-3p mimics in preparation of drugs for treating atherosclerosis |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114272257B (en) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110142913A1 (en) * | 2009-12-10 | 2011-06-16 | Kaohsiung Medical University | Composition and method for treating atherosclerosis, method for determining if a subject has atherosclerosis and method of screening an anti-atherosclerotic drug |
-
2022
- 2022-01-12 CN CN202210033057.6A patent/CN114272257B/en active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110142913A1 (en) * | 2009-12-10 | 2011-06-16 | Kaohsiung Medical University | Composition and method for treating atherosclerosis, method for determining if a subject has atherosclerosis and method of screening an anti-atherosclerotic drug |
Non-Patent Citations (5)
Title |
---|
刘亚密 等: "microRNA 调节细胞自噬影响动脉粥样硬化", 《中国动脉硬化杂志》 * |
宋翠珠 等: "MicroRNA对动脉粥样硬化发生的调控作用及其临床应用", 《中国生物化学与分子生物学报》 * |
李兰芳 等: "微小RNA 在动脉粥样硬化中的研究进展", 《中南医学科学杂志》 * |
谢晓暄 等: "微小RNA 在动脉粥样硬化中的作用及中药干预研究进展", 《西部中医药》 * |
顾燕妮 等: "miRNA 与动脉粥样硬化炎症机制研究进展", 《中国免疫学杂志》 * |
Also Published As
Publication number | Publication date |
---|---|
CN114272257B (en) | 2022-11-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Wang et al. | MiR-195-5p promotes cardiomyocyte hypertrophy by targeting MFN2 and FBXW7 | |
EP2374884A2 (en) | Human miRNAs isolated from mesenchymal stem cells | |
KR20160139849A (en) | Pharmaceutical composition comprising miR-7, miR-18a or miR-18b for prevention or treatment of metabolic disease | |
CN106701900A (en) | Long-chain noncoding RNA HERC2P3 gene and application thereof in gastric cancer | |
Okada et al. | Identification of a novel cis-acting element for fibroblast-specific transcription of the FSP1 gene | |
CN106754918A (en) | Applications of the MicroRNA in the caput femoris necrosis product for preventing or diagnosing glucocorticoid to cause | |
CN106701922A (en) | Application of micro RNA in preventing or treating femoral head necrosis caused by glucocorticoid | |
CN112126686B (en) | Early-stage screening molecular marker for renal fibrosis and application thereof | |
CN114272257B (en) | Application of miR-204-5p mimics or miR-204-3p mimics in preparation of drugs for treating atherosclerosis | |
CN109486816B (en) | Polynucleotide for treating tumor and its application | |
CN109097358B (en) | Application of lncRNA in prevention or treatment of hypertension | |
CN114517204B (en) | CircPOLK for tumor treatment target and diagnosis biomarker and application thereof | |
CN112746101B (en) | Osteoporosis diagnosis marker and nucleic acid medicine for promoting osteoporosis bone regeneration | |
CN110279706B (en) | Application of hnRNPC gene C1 and/or C2 subtype as drug target in screening anti-cancer drugs | |
CN111118143A (en) | Reagent for detecting and targeting RP11-754B17.1 and application thereof in arthritis | |
CN112266954B (en) | Application of miR-125b-2-3p in renal fibrosis | |
CN116426637B (en) | Application of ACTN2 in prediction or detection of gastric cancer bone marrow metastasis | |
CN108300763A (en) | A method of screening miR-101-3P target genes | |
CN110368502B (en) | Application of UTX gene in preparation of medicines for preventing or treating blood lipid diseases | |
CN111118139B (en) | Molecular target for osteoporosis and application thereof | |
CN112263587B (en) | Application of miR-3065-5p in preparation of medicine for preventing and/or treating renal fibrosis | |
CN112795644B (en) | Application of miRNA biomarker in diagnosis of myocardial fibrosis diseases | |
CN113498347B (en) | Use of Endothelial Progenitor Cells (EPC) for the treatment of premature senility syndrome diseases | |
CN113186276A (en) | Marker for coronary heart disease and treatment drug thereof | |
WO2020248771A9 (en) | Preparation method for diabetes early warning and/or diagnostic reagent kit based on hsa-mir-320a, medicament for preventing diabetes, screening method for medicament, and preparation method therefor |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |